VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
GSK
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
GSKGSK plc
$49.24$98.7B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksGSKFinancials

GSK plc (GSK) Income Statement

30Y historyFree accessUpdated daily

Gross margin held near 74.5% in 2026Q3 and operating margin ranged from 2.4% to 30.3% over the period, suggesting lumpy operating expenses such as the $3.5B R&D spike in 2026Q2 continue to drive earnings volatility.

Income StatementBalance SheetCash FlowRatios

GSK Income Statement

Annual statement

GSK Income Statement

GSK plc (GSK) annual income statement — 30-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue33.47B32.67B31.38B30.33B29.32B24.7B24.35B33.75B30.82B30.19B27.89B23.92B23.01B26.5B26.43B27.39B28.39B28.37B24.35B22.74B23.22B21.66B19.98B21.41B21.21B20.53B18.08B8.49B7.98B7.98B8.34B
Revenue Growth %4.06%4.11%3.46%3.42%18.74%1.4%-27.85%9.52%2.1%8.24%16.58%3.99%-13.2%0.28%-3.49%-3.54%0.08%16.49%7.1%-2.06%7.21%8.4%-6.71%0.95%3.3%13.58%112.94%6.35%0.04%-4.33%-20.49%
Cost of Goods Sold9.05B9.02B9.05B8.56B9.55B8.16B7.93B11.86B10.24B10.34B9.29B8.85B7.32B8.59B7.92B7.65B7.9B7.38B6.42B5.21B5.01B4.76B4.36B4.54B4.61B4.44B3.96B4.33B1.54B00
COGS % of Revenue-27.6%28.84%28.24%32.58%33.05%32.56%35.15%33.23%34.26%33.31%37.01%31.83%32.39%29.98%27.93%27.82%26.02%26.34%22.92%21.57%22%21.82%21.19%21.73%21.62%21.91%51.05%19.35%--
Gross Profit24.42B23.65B22.33B21.76B19.77B16.53B16.43B21.89B20.58B19.84B18.6B15.07B15.68B17.92B18.51B19.74B20.49B20.99B17.94B17.53B18.21B16.89B15.62B16.88B16.6B16.09B14.12B4.16B6.44B7.98B8.34B
Gross Margin %72.96%72.4%71.16%71.76%67.42%66.95%67.44%64.85%66.77%65.74%66.69%62.99%68.17%67.61%70.02%72.07%72.18%73.98%73.66%77.08%78.43%78%78.18%78.81%78.27%78.38%78.09%48.95%80.65%100%100%
Gross Profit Growth %-5.92%2.6%10.08%19.58%0.66%-24.97%6.37%3.71%6.69%23.42%-3.91%-12.48%-3.17%-6.25%-3.68%-2.35%17.01%2.33%-3.74%7.8%8.15%-7.44%1.64%3.16%14.01%239.68%-35.45%-19.32%-4.33%-20.49%
Operating Expenses17.59B15.31B18.31B15.02B13.34B12.18B10.45B14.93B15.1B15.76B16B4.75B12.09B10.89B11.21B11.93B16.71B12.56B10.8B9.59B10.4B16.53B9.87B10.49B11.05B9.99B9.39B1.53B3.75B5.16B5.21B
OpEx % of Revenue-46.87%58.35%49.52%45.48%49.3%42.89%44.23%48.98%52.2%57.37%19.85%52.53%41.09%42.4%43.57%58.86%44.29%44.33%42.17%44.81%76.32%49.39%49%52.1%48.66%51.93%18.03%47.04%64.64%62.45%
Selling, General & Admin9.34B9.09B11.02B9.38B8.37B7.07B7.44B11.4B9.91B9.67B9.37B9.23B8.25B8.48B8.79B8.51B12.75B9.59B7.66B6.82B7.25B7.25B7.2B7.57B07.47B00000
SG&A % of Revenue-27.82%35.11%30.95%28.55%28.63%30.54%33.78%32.17%32.04%33.58%38.59%35.84%31.99%33.25%31.07%44.9%33.81%31.44%30.01%31.25%33.47%36.03%35.36%-36.37%-----
Research & Development9.37B7.53B6.4B6.22B5.49B5.02B4.79B4.57B3.89B4.48B3.63B3.56B3.45B3.92B3.98B4.01B4.46B4.11B3.68B3.24B3.46B3.14B2.9B2.79B2.9B2.56B2.53B1.27B1.16B1.15B1.16B
R&D % of Revenue-23.04%20.4%20.52%18.71%20.32%19.68%13.53%12.63%14.83%13.01%14.88%15%14.8%15.05%14.64%15.7%14.47%15.12%14.25%14.89%14.48%14.53%13.02%13.67%12.47%13.97%14.95%14.57%14.39%13.92%
Other Operating Expenses-4M-1.3B891M-590M-523M87M-1.78B-1.04B1.29B1.61B3.01B-8.04B390M-1.51B-1.56B-587M-493M-1.14B-541M-475M-307.78M6.14B-235.13M133.28M8.15B-37.16M6.86B262M2.59B4.01B4.05B
Operating Income6.83B8.34B4.02B6.75B6.43B4.36B5.98B6.96B5.48B4.09B2.6B10.32B3.6B7.03B7.3B7.81B3.78B8.43B7.14B7.94B7.19B6.86B5.26B6.38B5.55B6.1B4.73B2.63B2.68B2.82B3.13B
Operating Margin %20.4%25.52%12.82%22.24%21.94%17.64%24.55%20.62%17.79%13.54%9.32%43.15%15.64%26.52%27.62%28.51%13.32%29.7%29.32%34.91%30.95%31.7%26.33%29.81%26.17%29.72%26.16%30.92%33.61%35.36%37.55%
Operating Income Growth %-107.36%-40.39%4.85%47.65%-27.13%-14.11%26.96%34.16%57.31%-74.83%186.96%-48.82%-3.73%-6.49%106.37%-55.1%17.98%-10.05%10.48%4.68%30.52%-17.61%15%-9.05%29.06%80.15%-2.16%-4.93%-9.9%31.49%
EBITDA9.03B10.65B6.57B9.04B8.58B6.48B8.03B9.29B7.34B6.01B4.37B11.95B5.08B8.44B8.74B9.23B5.46B9.99B8.37B8.96B8.14B7.77B6.12B7.24B6.38B6.92B5.46B3.05B3.04B3.19B3.54B
EBITDA Margin %26.99%32.61%20.95%29.8%29.26%26.24%32.97%27.54%23.81%19.91%15.68%49.96%22.09%31.85%33.09%33.7%19.24%35.21%34.38%39.41%35.08%35.87%30.63%33.82%30.05%33.68%30.22%35.96%38.09%40.04%42.46%
EBITDA Growth %-15.25%62.08%-27.29%5.35%32.43%-19.3%-13.62%26.65%22.13%37.44%-63.42%135.23%-39.81%-3.46%-5.25%68.99%-45.31%19.29%-6.58%10.04%4.83%26.97%-15.52%13.61%-7.82%26.57%78.97%0.39%-4.82%-9.8%21.51%
D&A (Non-Cash Add-back)2.21B2.31B2.55B2.29B2.15B2.12B2.05B2.33B1.86B1.92B1.77B1.63B1.48B1.41B1.45B1.42B1.68B1.56B1.23B1.02B958.04M903.7M858.68M859.04M824M812.8M735M428M358M373M410M
EBIT6.52B8.09B4.12B6.79B6.45B4.36B6.02B7.1B5.49B4.26B2.66B11.26B3.67B7.39B7.36B8.45B3.94B8.67B7.5B8.2B7.81B363.81M5.75B6.38B5.71B6.1B6.35B2.78B2.87B2.91B3.24B
Net Interest Income-631.5M-631M-590.19M-735M-791.26M-755M-852M-810.89M-665.8M-667M-662M-650M-628.53M-705M-662.96M-654.46M-687.53M-713M-530M-59.35M-65M-194M-186M0-133M0-159M-92M-91M-123M-187M
Interest Income108.77M56M67.39M40M64.27M28M44M98M77.83M65M72M104M67.67M61M72.02M87.88M77.83M70M313M255.5M287M257M176M073M0158M114M111M104M89M
Interest Expense740.28M687M657.58M775M855.53M784M892M912M743.64M734M736M757M696.2M767M734.97M742.34M765.36M783M843M314.85M352M451M362M161M206M1.15B317M206M202M227M276M
Other Income/Expense-1.46B-937M-544M-681M-805M-758M-809M-740M-683M-562M-659M204M-629M-381M-700M-109M-626M-534M-482M-402.39M285.49M234.1M188.63M-62.72M-45M-17.89M1.3B-50M-12M-136M-168M
Pretax Income5.37B7.4B3.48B6.06B5.63B3.6B5.17B6.22B4.8B3.52B1.94B10.53B2.97B6.65B6.6B7.7B3.16B7.89B6.66B7.54B7.47B7.1B5.45B6.32B5.51B6.09B6.03B2.58B2.67B2.69B2.96B
Pretax Margin %16.04%22.66%11.08%19.99%19.19%14.57%21.23%18.43%15.57%11.68%6.95%44%12.9%25.08%24.97%28.11%11.12%27.82%27.34%33.14%32.18%32.78%27.27%29.52%25.96%29.64%33.35%30.33%33.46%33.66%35.54%
Income Tax559.17M1.11B526M756M707M83M67M953M754M1.36B877M2.15B137M1.02B1.92B2.24B1.3B2.22B1.95B2.15B2.2B2.02B1.67B1.74B1.46B1.65B1.75B746M815M819M933M
Effective Tax Rate %10.42%15.02%15.13%12.47%12.56%2.31%1.3%15.32%15.71%38.47%45.23%20.46%4.62%15.33%29.12%29.1%41.31%28.16%29.24%28.59%29.5%28.46%30.72%27.47%26.53%27.12%28.98%28.97%30.51%30.49%31.48%
Net Income4.34B5.72B2.58B4.93B14.96B4.38B5.75B4.64B3.62B1.53B912M8.42B2.76B5.44B4.5B5.26B1.63B5.53B4.6B5.22B5.39B4.69B3.91B4.48B3.94B3.1B4.16B1.81B1.84B1.85B2B
Net Margin %12.96%17.5%8.21%16.25%51%17.76%23.61%13.76%11.76%5.08%3.27%35.2%11.98%20.51%17.02%19.21%5.76%19.5%18.9%22.95%23.2%21.65%19.55%20.91%18.55%15.1%23.02%21.33%23%23.18%23.94%
Net Income Growth %-21.03%121.98%-47.75%-67.05%241.07%-23.73%23.77%28.21%136.49%67.98%-89.17%205.59%-49.3%20.83%-14.48%221.97%-70.46%20.19%-11.83%-3.12%14.93%20.01%-12.78%13.81%26.94%-25.52%129.82%-1.36%-0.76%-7.36%36.97%
Net Income (Continuing)4.81B6.29B2.95B5.31B4.92B3.52B5.1B5.27B4.05B2.17B1.06B8.37B2.83B5.63B4.68B5.46B1.85B5.67B4.71B5.34B5.39B4.69B3.77B4.48B4.04B4.43B4.28B1.83B1.86B1.87B2.03B
Discontinued Operations000010.7B1.58B1.28B000000000000000000000000
Minority Interest-394.63M-420.26M-585M-703.69M-502M8.52B8.5B9.21B-688M3.56B3.84B3.76B673M815M937M795M858M737M387M307M262M259M213M744.24M807M863.73M1.24B51M66M47M42M
EPS (Diluted)2.132.781.242.407.322.702.862.321.820.780.464.301.422.762.262.580.802.702.202.342.362.041.701.921.661.261.681.241.261.281.42
EPS Growth %-19.17%124.19%-48.33%-67.21%171.11%-5.59%23.28%27.47%133.33%69.57%-89.3%202.82%-48.55%22.12%-12.4%222.5%-70.37%22.73%-5.98%-0.85%15.69%20%-11.46%15.66%31.75%-25%35.48%-1.59%-1.56%-9.86%26.79%
EPS (Basic)-2.821.262.447.442.742.882.341.840.780.484.361.442.822.302.620.802.722.222.362.382.061.701.941.661.261.701.261.281.301.42
Diluted Shares Outstanding2.04B2.06B2.07B2.06B2.04B1.62B2.02B2.01B1.99B1.98B1.96B1.96B1.95B1.97B2B2.04B2.05B2.04B2.09B2.23B2.28B2.29B2.29B2.32B2.37B2.45B2.45B2.91B2.91B2.88B2.82B
Basic Shares Outstanding2B2.03B2.04B2.03B2.01B1.6B1.99B1.98B1.97B1.95B1.94B1.93B1.92B1.93B1.96B2.01B2.03B2.03B2.08B2.21B2.26B2.28B2.29B2.31B2.36B2.43B2.43B2.9B2.88B2.85B2.82B
Dividend Payout Ratio-43.87%94.91%56.68%28.55%91.2%69.18%85.1%108.39%254.96%531.8%46%139.44%67.7%84.77%64.74%196.14%54.29%63.65%53.51%48.22%50.99%63.36%52.03%59.14%75.18%-----

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetHealthy
Cash FlowStable
Top Statement Risk

Legacy litigation and HIV generic exposure

Top-Line Growth Decelerating Toward Low Single Digits

Based on reported quarterly figures, GSK's revenue growth has moderated from roughly 9.8% in 2024Q2 to a range of 1.5% to 6.7% across recent quarters, indicating growth that is positive but no longer accelerating.

The reported series shows volatility rather than a clean trend, with the highest growth prints coming from the most recent 2026Q3 quarter at 3.2% and 2025Q3 at 6.7%. This pattern suggests that vaccine timing and government procurement cycles may be driving much of the quarter-to-quarter variation rather than a durable step-change in demand. Investors should monitor whether the Arexvy and Shingrix franchises can sustain mid-single-digit growth once legacy respiratory and HIV volumes face pricing pressure.

High Gross Margins Anchored by Specialty Mix

GSK's gross margin has held in a 68.5% to 75.4% band across the ten reported quarters, with the 74.5% print in 2026Q3 suggesting the specialty and vaccine mix continues to carry the portfolio.

The margin profile sits at the upper end of the large-cap pharma peer set, which indicates that pricing power in HIV and differentiated vaccines is offsetting the lower-margin legacy respiratory and antibiotic volumes. The dip toward 68.5% in 2024Q4 appears to align with seasonal procurement mix rather than a structural shift, though this remains an inference from the data provided. Sustained margins near 75% would depend on continued HIV franchise pricing and avoiding a faster-than-expected erosion from generic entrants.

Operating Margin Swings Reflect Lumpy Opex

Reported operating margins ranged from 2.4% to 30.3% over the period, and the gap between gross and operating margin widened sharply in 2024Q3 and 2026Q2, according to the reported income statement figures.

Operating income appears far more sensitive to SG&A and R&D timing than to gross profit, as the 2024Q3 SG&A spike to $3.8B collapsed operating margin despite stable gross profit of $5.6B. This suggests that the cost base carries substantial discretionary or lumpy components, making operating leverage unreliable on a quarterly basis. The recovery to 28.9% in 2026Q3 indicates the business can convert gross profit efficiently when opex normalizes.

Net Income Volatility Warrants Adjusted Earnings Scrutiny

Net income has swung from a loss of $58.0M in 2024Q3 to $2.0B in 2025Q3, and EPS growth figures ranging from -103.9% to 56.0% suggest headline earnings are heavily affected by non-recurring items.

The magnitude of these swings relative to revenue indicates that legal provisions, restructuring charges, and portfolio-related adjustments may be materially influencing reported results, consistent with the known gap between IFRS and adjusted figures. Stock-based compensation is reported as zero across the period, so its impact on quality cannot be assessed from this data. Investors should reconcile reported EPS against adjusted EPS before drawing conclusions about underlying earnings power.

Legacy Litigation and Opex Could Compress Margins

Bears would point to the 2024Q3 operating margin collapse to 2.4% and the 2026Q2 R&D spike to $3.5B as evidence that unpredictable legal and development costs could erode the margin base.

A bearish reading would argue that recurring R&D intensity and unprovisioned Zantac-related exposure may keep operating income volatile even when gross margins remain strong. If HIV generic competition accelerates, the high gross margin buffer could narrow faster than new franchises like RSV can offset. This interpretation rests on the reported figures and warrants further investigation into provisioning disclosures.

GSK — Frequently Asked Questions

Quick answers to the most common questions about buying GSK stock.

What was GSK plc's (GSK) revenue in 2025?

For fiscal year 2025, GSK plc (GSK) reported total revenue of $32.67B. This represents a 291.6% increase compared to $8.34B in 1996.

Is GSK plc (GSK) profitable?

GSK plc (GSK) is profitable, generating $5.72B in net income for the fiscal year ending 2025 with a net profit margin of 17.5%.

What is GSK plc's operating profit margin?

GSK plc (GSK) reported an operating income of $8.34B, resulting in an operating profit margin of 25.5%. This margin reflects the operational efficiency of the business before interest and taxes.

What is GSK plc's gross profit and gross margin?

GSK plc (GSK) generated $23.65B in gross profit for the year, representing a gross profit margin of 72.4%. This demonstrates the company's core pricing power and production efficiency.